To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions

Breast Neoplasms

Interventions

DRUG

Docetaxel

Trial Locations (2)

Sanofi-Aventis, Vienna

Sanofi-aventis, Warsaw